Welly he is working at the point where clinicians and medical device manufacturers meet. Hence, those are the only standards to measure against.

If those standards are met, great, more power to NeuralRad. It just rubs some people wrong to market this in classic SV start-up fashion, using the latest, in this case AI, hype. It just rubs people in more serious industrues the wrong way sometimes. Which, by the way, is valid feedback for everyone on HN with a B2B start-up targeting clients in very mature and risk averse indistries.